Education
About Us
Working with TipRanks
Follow Us
Shield Therapeutics PLC (GB:STX)
LSE:STX
Total Valuation
Shield Therapeutics has a market cap or net worth of £24.48M. The enterprise value is ―.
Market Cap£24.48M
Enterprise Value―
Share Statistics
Shield Therapeutics has 1,041,690,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,041,690,400
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Shield Therapeutics’s return on equity (ROE) is 20.23 and return on invested capital (ROIC) is -91.98%.
Return on Equity (ROE)20.23
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)-91.98%
Return on Capital Employed (ROCE)-0.91
Revenue Per Employee399.74K
Profits Per Employee-337.66K
Employee Count63
Asset Turnover0.55
Inventory Turnover3.23
Valuation Ratios
The current PE Ratio of Shield Therapeutics is -1.15. Shield Therapeutics’s PEG ratio is ―.
PE Ratio-1.15
PS Ratio0.00
PB Ratio-18.96
Price to Fair Value-23.24
Price to FCF-3.43
Price to Operating Cash Flow-2.88
PEG Ratio―
Income Statement
In the last 12 months, Shield Therapeutics had revenue of 25.18M and earned -21.27M in profits. Earnings per share was -0.02.
Revenue25.18M
Gross Profit10.57M
Operating Income-17.98M
Pretax Income-20.78M
Net Income-21.27M
EBITDA-16.58M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -6.94M and capital expenditures -800.14K, giving a free cash flow of -7.74M billion.
Operating Cash Flow-6.94M
Free Cash Flow-7.74M
Free Cash Flow per Share>-0.01
Dividends & Yields
Shield Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.69
52-Week Price Change34.29%
50-Day Moving Average2.76
200-Day Moving Average3.27
Relative Strength Index (RSI)41.23
Average Volume (3m)1.81M
Important Dates
Shield Therapeutics upcoming earnings date is Sep 4, 2025, TBA Not Confirmed.
Last Earnings DateApr 24, 2025
Next Earnings DateSep 4, 2025
Ex-Dividend Date―
Financial Position
Shield Therapeutics as a current ratio of 1.16, with Debt / Equity ratio of -2002.28%
Current Ratio1.16
Quick Ratio0.99
Debt to Market Cap0.86
Net Debt to EBITDA-0.93
Interest Coverage Ratio-5.82
Taxes
In the past 12 months, Shield Therapeutics has paid 489.90K in taxes.
Income Tax489.90K
Effective Tax Rate-0.02
Enterprise Valuation
Shield Therapeutics EV to EBITDA ratio is -2.41, with an EV/FCF ratio of -5.67.
EV to Sales1.58
EV to EBITDA-2.41
EV to Free Cash Flow-5.67
EV to Operating Cash Flow-5.69
Balance Sheet
Shield Therapeutics has £5.61M in cash and marketable securities with £21.06M in debt, giving a net cash position of £15.45M billion.
Cash & Marketable Securities£5.61M
Total Debt£21.06M
Net Cash£15.45M
Net Cash Per Share£0.01
Tangible Book Value Per Share>-£0.01
Margins
Gross margin is 43.84%, with operating margin of -71.38%, and net profit margin of -84.47%.
Gross Margin43.84%
Operating Margin-71.38%
Pretax Margin-82.52%
Net Profit Margin-84.47%
EBITDA Margin-65.82%
EBIT Margin-70.25%
Analyst Forecast
The average price target for Shield Therapeutics is £3.80, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target£3.80
Price Target Upside61.70% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast139.31%
EPS Growth Forecast34.05%